Recent coverage around Niagen Bioscience (NAGE) has focused on upcoming launches with major consumer product partners and fresh clinical data tied to its FDA recognized nicotinamide riboside, which has pushed the stock back onto investors’ watchlists.

Despite the recent excitement around new partner launches and clinical readouts, Niagen Bioscience’s share price has pulled back. The 30 day share price return shows a 24.11% decline and the 90 day share price return shows a 25% decline, while the 3 year total shareholder return of 181.87% shows how strong the prior run up has been and suggests recent momentum has cooled from earlier levels.

If this kind of volatility has you looking wider across the market, it could be worth checking out our screener of 22 top founder-led companies as a way to surface other potential ideas beyond Niagen Bioscience.

With revenue of $124.709 and net income of $20.429, alongside an intrinsic discount of 72.87% and a 3 year total return of 181.87%, you have to ask yourself: is Niagen Bioscience mispriced, or is the market already baking in future growth?

Most Popular Narrative: 68% Undervalued

Niagen Bioscience’s most followed narrative points to a fair value of $16.04 versus a last close of $5.13, which is a wide gap that hinges on specific assumptions about future growth and profitability.

Planned increases in R&D investments, alongside a potential investigational drug application for the use of NR in the treatment of ataxia telangiectasia, could lead to future earnings growth if successful pharmaceutical developments result in new, high-margin products. The resolution of reversals of royalty obligations and recoveries from legal settlements contribute to a stronger balance sheet, potentially allowing for reinvestment in growth initiatives and enhancing future net income stability.

Want to see what kind of revenue path and profit margins have to line up for that valuation gap to make sense? The narrative leans heavily on rapid earnings expansion, richer margins from higher value products, and a premium multiple that sits above the wider industry. Curious how those pieces fit together and which assumptions do the heavy lifting in the fair value math?

Result: Fair Value of $16.04 (UNDERVALUED)

However, this depends on competition in NAD boosters not eroding Niagen’s position and on regulatory or legal outcomes not curbing key products or future approvals.

Build Your Own Niagen Bioscience Narrative

If you are not fully aligned with this view or simply prefer to test the numbers yourself, you can build a custom story for Niagen in just a few minutes by starting with Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Niagen Bioscience.

Looking for more investment ideas?

If you like Niagen’s story but do not want all your hopes tied to one ticker, now is the time to widen your opportunity set.

• Spot potential value opportunities early by scanning our list of 55 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them.
• Prioritise staying power by reviewing our solid balance sheet and fundamentals stocks screener (46 results) where financial strength is front and center in the screening criteria.
• Get ahead of the crowd by running your eye over a screener containing 25 high quality undiscovered gems that most investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.